On Moday, Invivo Therapeutics Holdings Corp (OTC:NVIV) started to move up. Yesterday, the stock hit a spectacular gain by 
adding 56.58% to its price and trading over 638 thousand shares for the day.
The reason for the gain is crystal clear – stock alerts. The first one came up on Oct 30 on the website seekingalpha.com. The promoter featured Invivo’s technology and pointed out that the company was just awaiting a green light from the FDA to begin the first trial in humans.
The alert certainly sounds quite optimistic and it is not the only one of that kind. Yesterday, NVIV got promoted by Mister X, who put the stock on its watchlist for the day. Apparently, Invivo has held the campaign by itself as there was no third party involved in it.
Apart from the alerts, the last news about NVIV can be found on Internet. A week ago, Invivo reported that it was going to present its latest advances at the FSX Broker Dealer Conference on Oct 26-29 this year. Though, the news stated that the company was still waiting for an FDA approval to begin its clinical trials.[BANNER]
Another announcement on Invivo’s official website reported that the company’s CEO Frank Reynolds has been selected to serve as a judge in the Massachusetts Institute of Technology’s 22nd Annual $100K Entrepreneurship Competition. However, no particular information on the company’s business operations was released.
Regarding the financials of NVIV, these don’t look that encouraging. On the contrary, as of June 30 the company’s liabilities are substantially higher than its assets, while the stockholders’ deficit is approximately $4 million. Besides, Invivo has incurred a huge net loss and its accumulated deficit keeps increasing.
And while waiting for its FDA approvals, Invivo’s management states that it will need to raise substantial additional capital to complete its clinical trials, obtain marketing approvals and commercialize its products.
